XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 131 filers reported holding XENON PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,598,053 | -9.3% | 171,378 | -15.7% | 0.55% | +8.9% |
| Q1 2023 | $7,275,105 | -33.1% | 203,272 | -26.3% | 0.51% | -46.7% |
| Q4 2022 | $10,871,009 | +16.0% | 275,704 | +6.2% | 0.95% | +17.2% |
| Q3 2022 | $9,371,993 | -33.9% | 259,612 | -44.3% | 0.81% | -19.4% |
| Q2 2022 | $14,173,013 | +13.1% | 465,911 | +13.6% | 1.01% | +4.8% |
| Q1 2022 | $12,534,342 | +91.5% | 410,021 | +95.7% | 0.96% | +130.1% |
| Q4 2021 | $6,545,374 | +706.2% | 209,519 | +192.7% | 0.42% | +106.9% |
| Q1 2020 | $811,842 | -71.3% | 71,591 | -66.8% | 0.20% | -59.5% |
| Q4 2019 | $2,826,634 | +45.5% | 215,609 | 0.0% | 0.50% | -17.2% |
| Q3 2019 | $1,942,637 | -12.2% | 215,609 | -3.9% | 0.60% | -2.6% |
| Q2 2019 | $2,211,992 | -3.0% | 224,340 | 0.0% | 0.62% | -6.9% |
| Q1 2019 | $2,279,294 | +76.1% | 224,340 | +9.4% | 0.66% | -5.1% |
| Q4 2018 | $1,294,206 | -53.3% | 205,104 | -2.2% | 0.70% | -42.3% |
| Q3 2018 | $2,768,555 | – | 209,739 | – | 1.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |